Omada Health (OMDA) Q2 2026: Gross Margin Jumps 700bps as Multi-Condition Expansion Accelerates
Omada’s Q2 marked a decisive margin inflection, with gross margin up 700 basis points year over year, as the company’s multi-condition chronic care platform deepened its reach across employers, health plans, and pharmacy benefit managers (PBMs). Record member growth and program diversification fueled both top-line and bottom-line outperformance, prompting a guidance raise and setting up for a robust 2027 benefit cycle. Leadership transition and AI-driven efficiency gains now frame the next phase of Omada’s strategic evolution.
Summary
- Margin Expansion Signals Model Scalability: AI and operational leverage drove gross margin to new highs.
- Multi-Condition Suite Drives Member Growth: Diabetes, hypertension, and new cholesterol programs accelerated member and revenue mix shift.
- Leadership Transition Sets Strategic Course: Incoming CEO to double down on channel, product, and AI momentum for 2027.
Business Overview
Omada Health is a digital chronic care platform, delivering virtual programs for diabetes, hypertension, obesity, and related conditions to employer groups, health plans, and PBMs. The company earns revenue primarily per-member-per-month (PMPM), billing for care activity rather than flat subscriptions, with a multi-condition suite spanning prevention, management, and wraparound GLP-1 support. Its business model is anchored in scaling evidence-based, tech-enabled care to large populations, with a growing emphasis on channel partnerships and AI-driven efficiency.
Performance Analysis
Q2 2026 was a record-setting quarter, with Omada reporting its highest-ever revenue, gross margin, and net income. Revenue growth was broad-based, up 43% year over year, with diabetes and hypertension programs outpacing overall growth and driving a healthy shift toward higher-value offerings. Gross margin expanded meaningfully, reaching 73% GAAP, up 700 basis points YoY, reflecting improved cost structure from AI adoption and operational efficiency in care delivery.
Membership growth was equally notable, with 1.1 million total members at quarter end, up 45% YoY. Trailing 12-month revenue per member held steady, signaling durable unit economics despite rapid cohort expansion. Cost to serve per member declined over 10% YoY, with AI and digital tools amplifying care team productivity and engagement duration. Operating leverage improved, with non-GAAP operating expenses down to 62% of revenue from 68% a year ago, and adjusted EBITDA rising sharply. The balance sheet remained strong, with $222 million in cash and no debt.
- AI-Driven Cost Efficiency: Cost of revenue per member fell over 10% YoY, supporting margin gains and freeing resources for growth investments.
- Product Mix Shift: Diabetes and hypertension programs, Omada’s highest-priced and longest-duration offerings, accelerated revenue and member growth, reducing reliance on any single product.
- Channel Diversification: Expansion with HCSC and multiple PBMs broadened Omada’s installed base and accelerated pipeline conversion, especially for new products like cholesterol and GLP-1 prescribing.
The quarter’s performance validates Omada’s ability to scale profitably, with sustainable economics and a robust pipeline supporting raised full-year guidance.
Executive Commentary
"Year over year, we delivered 43% revenue growth and expanded gross margin by 700 basis points to 73% on a GAAP basis and by 600 points to 74% on a non-GAAP basis. We also generated $5 million in net income and $11 million in adjusted EBITDA versus a loss a year ago. Once again, we exceeded consensus, enabling us to raise our full-year outlook."
Wei-Li Shao, President and Incoming Chief Executive Officer
"Q2 also marked our second quarter of GAAP net income profitability, following the fourth quarter of 2025. These are meaningful milestones for the business, and we believe they reflect the structural profitability of the model we are building."
Steve Cook, Chief Financial Officer
Strategic Positioning
1. Multi-Condition Platform Expansion
Omada’s ability to cross-sell and upsell new programs—notably cholesterol and GLP-1 prescribing—has broadened its addressable market (TAM, total addressable market) and deepened customer relationships. The company’s cardiometabolic suite now spans prevention, diabetes, hypertension, cholesterol, and GLP-1 management, positioning Omada as a one-stop solution for employers and payers seeking comprehensive chronic care support.
2. Channel Penetration and Embedded Distribution
Strategic wins with major PBMs and health plans, including the HCSC fully insured expansion, have increased Omada’s covered lives and reduced sales cycle friction. Embedded benefit design, especially in fully insured books, enables faster member activation and revenue ramp, while channel partnerships amplify Omada’s reach without proportional salesforce expansion.
3. AI and Operational Leverage
AI has become a core driver of Omada’s margin structure, powering both member-facing personalization and care team productivity. Tools like Omada Spark and MealMap have increased engagement duration by nearly 10% YoY, while standardized workflows and predictive analytics have reduced cost to serve. Leadership sees AI as a lever for ongoing operating leverage as the business scales.
4. Leadership Transition and Strategic Continuity
Founder Sean Duffy’s move to executive chair and the elevation of Wei-Li Shao to CEO signal both continuity and renewed focus on execution. Wei-Li’s tenure as president and CCO has been marked by channel expansion and product innovation, and his stated priorities include further leveraging AI, accelerating channel momentum, and deepening clinical impact across the member base.
Key Considerations
Omada’s Q2 results underscore the company’s transition from high-growth disruptor to scaled, structurally profitable platform. The following considerations frame the strategic context for investors:
- Channel Momentum: Recent expansions with PBMs and HCSC increase Omada’s installed base and pipeline visibility for 2027 and beyond.
- Product Breadth as a Hedge: The company’s multi-condition suite insulates against single-program risk and supports cross-sell economics.
- AI as a Margin Engine: Ongoing investment in AI and automation is driving both gross margin gains and sustainable cost structure.
- Seasonality and Pipeline Build: Omada’s business cadence is weighted toward Q1 enrollments, with H2 focused on pipeline development and customer acquisition for the next benefit cycle.
- Leadership Stability: The CEO transition is structured to preserve strategic momentum and capitalize on recent channel and product wins.
Risks
Omada faces several material risks, including potential volatility in employer decisions around GLP-1 coverage, evolving competitive dynamics in digital health, and the inherent seasonality of benefit cycles. While channel diversification and product breadth provide some insulation, rapid changes in payer coverage or regulatory frameworks could impact enrollment and revenue conversion. Investors should watch for shifts in employer benefit design, especially regarding GLP-1 reimbursement, and monitor Omada’s ability to sustain margin gains as it invests in new programs and AI capabilities.
Forward Outlook
For Q3 and Q4 2026, Omada guided to:
- Continued revenue growth, but at a moderated rate due to typical seasonality and a strong first-half comp.
- Operating expenses to remain flat or tick up slightly as Q1 hiring annualizes.
For full-year 2026, management raised guidance:
- Revenue of $334 million to $340 million (midpoint 30% YoY growth).
- Adjusted EBITDA of $21 million to $27 million (midpoint nearly 4x 2025).
Management highlighted several factors that frame the outlook:
- First-half enrollments will continue to generate revenue at healthy unit economics through year-end.
- Major enrollment inflection expected with the 2027 benefit cycle, as new covered lives from recent channel expansions activate.
Takeaways
Omada’s Q2 marks a structural shift in profitability and scale, with AI and channel leverage driving sustainable economics and a robust pipeline for 2027.
- Margin Inflection: Gross margin and EBITDA gains reflect durable cost discipline and AI-driven operating leverage.
- Pipeline Visibility: Channel and product expansions have set the stage for continued multi-year growth, with embedded distribution reducing sales friction.
- Strategic Watchpoint: Investors should monitor employer GLP-1 coverage decisions and Omada’s ability to sustain cross-sell momentum and margin trajectory into 2027.
Conclusion
Omada’s Q2 2026 delivered a decisive profitability inflection, with strong execution across product, channel, and operational efficiency. The company is well-positioned for continued growth, with margin structure, leadership continuity, and a robust pipeline supporting its long-term platform thesis.
Industry Read-Through
Omada’s results offer a clear signal for the digital health and chronic care sector: scalable, multi-condition platforms with embedded distribution and AI-powered efficiency are achieving both growth and profitability inflections. Channel partnerships with PBMs and health plans are emerging as critical go-to-market levers, reducing acquisition costs and accelerating member ramp. The durable economics and margin gains seen here raise the bar for competitors, while the evolving GLP-1 benefit landscape will pressure all players to demonstrate both outcomes and cost control. Investors in digital health should prioritize models with proven cross-sell, channel leverage, and AI-driven operating discipline.